FDA Clears Flublok, First Flu Vaccine Using Recombinant Insect Cell Technology
The U.S. Food and Drug Administration approved Flublok, marking the first influenza vaccine to use genetically modified proteins derived from insect cells. Manufactured by Protein Sciences Corporation, the vaccine employs recombinant DNA technology and a baculovirus — a type of virus that infects insects — to accelerate the production process compared to traditional egg-based manufacturing methods.
Flublok is a trivalent vaccine, meaning it targets three separate influenza strains. The production method involves extracting cells from the fall armyworm caterpillar and genetically engineering them to produce large quantities of hemagglutinin, a protein found on the surface of influenza viruses that facilitates viral entry into human cells.
Listed Side Effects and Clinical Trial Results
The vaccine’s package insert lists several potential adverse effects. Among the most serious is Guillain-Barre Syndrome, a rare neurological condition that causes the immune system to attack peripheral nerves. The manufacturer’s own warnings state that if a patient has experienced GBS within six weeks of a prior influenza vaccination, the decision to administer Flublok should involve careful consideration of potential benefits and risks.
Additional side effects documented in the package literature include allergic reactions, respiratory infections, headaches, fatigue, altered immune function, rhinorrhea, and muscle pain.
During clinical trials, two study participants died. Despite these outcomes, the manufacturer maintained that the vaccine met safety and efficacy standards, reporting approximately 45 percent effectiveness against circulating influenza strains.
Flucelvax: A Second Non-Traditional Flu Vaccine Using Dog Kidney Cells
The FDA had also approved Flucelvax several months earlier, a flu vaccine produced by Novartis using canine kidney cells instead of egg cultures. Like Flublok, this vaccine can be manufactured more rapidly than traditional formulations, giving producers the capacity to scale up quickly in the event of a declared pandemic.
Both vaccines were developed with support from a $1 billion taxpayer-funded grant issued by the U.S. Department of Health and Human Services in 2006. The grant was specifically intended to advance new manufacturing methods for vaccines, with the goal of being able to produce hundreds of millions of doses for rapid distribution during public health emergencies.
Additional Recombinant Vaccines in Development
At the time of Flublok’s approval, at least two other flu vaccines using genetically modified components were reportedly in development. One, being produced by Novavax, was designed to use virus-like particles — fragments of genetic material grown in caterpillar cells that mimic the structure of an influenza virus without containing live viral material.
These developments represented a broader industry shift away from egg-based vaccine production toward cell-culture and recombinant technologies, driven by both speed-to-market advantages and the desire to eliminate egg allergy concerns that affect a subset of the population.
